loading
Unicycive Therapeutics Inc stock is traded at $0.5953, with a volume of 1.09M. It is up +6.06% in the last 24 hours and down -8.33% over the past month. Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
See More
Previous Close:
$0.5532
Open:
$0.5768
24h Volume:
1.09M
Relative Volume:
1.26
Market Cap:
$71.22M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-0.3841
EPS:
-1.55
Net Cash Flow:
$-18.30M
1W Performance:
-2.22%
1M Performance:
-8.33%
6M Performance:
-13.45%
1Y Performance:
-37.97%
1-Day Range:
Value
$0.567
$0.6199
1-Week Range:
Value
$0.541
$0.6199
52-Week Range:
Value
$0.202
$0.9606

Unicycive Therapeutics Inc Stock (UNCY) Company Profile

Name
Name
Unicycive Therapeutics Inc
Name
Phone
650-384-0642
Name
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Name
Employee
22
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
UNCY's Discussions on Twitter

Compare UNCY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
UNCY
Unicycive Therapeutics Inc
0.5904 73.10M 0 -30.54M -18.30M -1.55
Biotechnology icon
ONC
Beigene Ltd Adr
237.21 25.23B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.73 113.16B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2506 40.65M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.87 64.41B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
74.95 6.18B 0 -153.72M -103.81M -2.00

Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-21-25 Initiated Guggenheim Buy
Apr-04-24 Initiated Piper Sandler Overweight

Unicycive Therapeutics Inc Stock (UNCY) Latest News

pulisher
May 22, 2025

Unicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor Conferences - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire Inc.

May 22, 2025
pulisher
May 21, 2025

Benchmark maintains $3 target on Unicycive stock post-Q1 filings By Investing.com - Investing.com Canada

May 21, 2025
pulisher
May 21, 2025

Unicycive Therapeutics Updates Annual Meeting Time - TipRanks

May 21, 2025
pulisher
May 21, 2025

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Unicycive Therapeutics Updates Annual Meeting Schedule: Key Details for Kidney Disease Biotech Investors - Stock Titan

May 21, 2025
pulisher
May 19, 2025

These Numbers Show Just How Powerful Unicycive Therapeutics Inc (NASDAQ: UNCY) Stock ‎Is - Stocksregister

May 19, 2025
pulisher
May 19, 2025

Q2 Earnings Forecast for UNCY Issued By Noble Financial - Defense World

May 19, 2025
pulisher
May 15, 2025

Data-Based Analysis Of Unicycive Therapeutics Inc (UNCY) - Stocksregister

May 15, 2025
pulisher
May 14, 2025

Unicycive (UNCY) Advances Toward FDA Approval for Key Kidney Disease Drug | UNCY Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Unicycive Reports Strong Q1 Results as Game-Changing Kidney Drug Nears FDA Decision Date - Stock Titan

May 14, 2025
pulisher
May 14, 2025

Unicycive Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 14, 2025
pulisher
May 10, 2025

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 07, 2025

Analysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before Long - Yahoo Finance

May 07, 2025
pulisher
May 03, 2025

Geode Capital Management LLC Acquires 122,089 Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - Defense World

May 03, 2025
pulisher
May 01, 2025

Insider’s View: Deciphering Unicycive Therapeutics Inc (UNCY)’s Financial Health Through Ratios - DWinneX

May 01, 2025
pulisher
May 01, 2025

Unicycive Therapeutics Inc (UNCY)’s stock performance: a year in review - uspostnews.com

May 01, 2025
pulisher
Apr 30, 2025

XTX Topco Ltd Raises Stock Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - Defense World

Apr 30, 2025
pulisher
Apr 25, 2025

Ratios Uncovered: Breaking Down Unicycive Therapeutics Inc (UNCY)’s Trailing Twelve Months Metrics - DWinneX

Apr 25, 2025
pulisher
Apr 23, 2025

What is the investor’s view on Unicycive Therapeutics Inc (UNCY)? - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Guggenheim Begins Coverage on Unicycive Therapeutics (NASDAQ:UNCY) - The AM Reporter

Apr 23, 2025
pulisher
Apr 22, 2025

Unicycive Therapeutics (NASDAQ:UNCY) Coverage Initiated by Analysts at Guggenheim - Defense World

Apr 22, 2025
pulisher
Apr 21, 2025

Guggenheim Initiates Coverage of Unicycive Therapeutics (UNCY) with Buy Recommendation - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Guggenheim Initiates Unicycive Therapeutics at Buy With $6 Price Target - marketscreener.com

Apr 21, 2025
pulisher
Apr 19, 2025

Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update - ADVFN

Apr 19, 2025
pulisher
Apr 13, 2025

HC Wainwright Reiterates “Buy” Rating for Unicycive Therapeutics (NASDAQ:UNCY) - Defense World

Apr 13, 2025
pulisher
Apr 11, 2025

H.C. Wainwright maintains Unicycive Buy rating, $7.50 target By Investing.com - Investing.com Canada

Apr 11, 2025
pulisher
Apr 11, 2025

Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate - TipRanks

Apr 11, 2025
pulisher
Apr 10, 2025

Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis - GlobeNewswire

Apr 10, 2025
pulisher
Apr 10, 2025

Breakthrough: Unicycive's New Kidney Drug Cuts Pills in Half, 98% of Patients Report Easy Use - Stock Titan

Apr 10, 2025
pulisher
Apr 08, 2025

Unicycive Therapeutics Inc Inc. (UNCY) Price Performance: A Technical Analysis Perspective - investchronicle.com

Apr 08, 2025
pulisher
Apr 07, 2025

60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 05, 2025

HC Wainwright Issues Pessimistic Estimate for UNCY Earnings - Defense World

Apr 05, 2025
pulisher
Apr 05, 2025

UNCY FY2025 EPS Lifted by Brookline Capital Management - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Brookline Capital Management Weighs in on UNCY Q1 Earnings - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

HC Wainwright Issues Positive Forecast for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Unicycive stock target raised to $7.50 by H.C. Wainwright - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Exclusive Look: Unicycive Unveils Latest Kidney Disease Breakthroughs at Major Healthcare Conference - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Unicycive Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

FDA to Review Unicycive's Kidney Disease Drug in June 2025: Key Financial Updates - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

Unicycive Approaches Its First Approval, But In A Competitive Space - insights.citeline.com

Mar 27, 2025
pulisher
Mar 25, 2025

Targeting Pressing Unmet Needs in Kidney Diseases with Unicycive Therapeutics CEO Dr. Shalabh Gupta - iHeart

Mar 25, 2025
pulisher
Mar 20, 2025

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 13, 2025

Unicycive to Highlight Patient Reported Outcomes Data at - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Revolutionary Dialysis Treatment Cuts Pill Burden in Half: Key Clinical Data Coming - StockTitan

Mar 13, 2025

Unicycive Therapeutics Inc Stock (UNCY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.18
price up icon 3.48%
$31.00
price down icon 1.26%
$591.19
price up icon 0.64%
$289.96
price up icon 1.93%
$4.22
price down icon 0.71%
$75.88
price up icon 1.88%
Cap:     |  Volume (24h):